Identification of APEX2 as an oncogene in liver cancer

doi:10.12998/wjcc.v8.i14.2917

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8869)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series.

Item

Count

PDF

508

WORD

204

HTML

4286

Figures (1-7)

420

Sum=5418

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

395

Download

805

Sum=1200

Publishing Process of This Article

Item

Count

Browse

628

Download

1623

Sum=2251

Jul 26, 2020 (publication date) through Sep 8, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Cases. Jul 26, 2020; 8(14): 2917-2929
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.2917

Full Size Figure Download Figure

Figure 3 The higher APEX2 level shows a lower overall survival rate. A: The total liver hepatocellular carcinoma patients, B: Patients with AJCC-T1 stage, C: Patients with positive hepatitis virus, D: Patients with negative hepatitis virus were divided into two groups (high or low-level group). The best cut-off was achieved by the interactive tool of Kaplan Meier plotter, and the overall survival rate was analyzed in 5-year following up. HR: Hazard ratio; OS: Overall survival; AJCC: The American Joint Committee on Cancer.

Citation: Zheng R, Zhu HL, Hu BR, Ruan XJ, Cai HJ. Identification of APEX2 as an oncogene in liver cancer. World J Clin Cases 2020; 8(14): 2917-2929
URL: https://www.wjgnet.com/2307-8960/full/v8/i14/2917.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i14.2917